Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Terns Pharmaceuticals
Biotech
Merck flies toward CML asset with $6.7B Terns acquisition
Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the New Jersey Big Pharma.
Will Maddox
Mar 25, 2026 10:28am
Biotech’s top 5 stock picks for 2026: analyst
Dec 23, 2025 10:05am
Terns mothballs obesity program after phase 2 data fall short
Oct 22, 2025 7:15am
Terns vows to stop funding metabolic disease trials beyond 2025
Aug 6, 2025 6:20am
Tern oral GLP-1 shows 5% weight loss at one month, highest dose
Sep 9, 2024 9:13am
Takeda taps new head of US oncology business—Chutes & Ladders
Aug 2, 2024 8:30am
